Abstract 91P
Background
Pulmonary metastasis is the most frequently occurring distant metastases of hepatocellular carcinoma (HCC). However, the indicated mechanism of pulmonary metastasis in HCC remains unclarified. Erythroid progenitor-differentiated myeloid cells (EDMCs) were reported to mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. The role of EDMCs in the metastasis of HCC and the development of pulmonary metastasis was investigated here.
Methods
The existence of EDMCs in the circulation and spleen of HCC mouse model were validated through Flow Cytometry. EDMCs were sorted using fluorescence-activated cell sorting. CFSE stained EDMCs transfer experiment were conducted to evaluated the Pulmonary metastasis promoting role in HCC mouse model. The transwell migration and invasion experiment of hepa1-6 cells (HCC cell line) cocultured with EDMCs were performed.
Results
Mouse with Pulmonary metastasis of HCC showed higher level of EDMCs in the circulation and spleen than those without Pulmonary metastasis. CFSE EDMCs stained with 5,6- carboxyfluorescein diacetate, succinimidyl ester (CFSE) were detected in the lung of HCC mouse after infusion though caudal vein and those infused mice developed more frequency of pulmonary metastasis than those without EDMCs infusion. IN the coculture experiment EDMCs promoted the migration and invasion of hepa1-6 cells.
Conclusions
EDMCs existed in the circulation of HCC mouse model. EDMCs could migrated from the circulation to the lung of HCC mice. EDMCs could facilitate migration and invasion of hepa1-6 cells migrate and invade. Thus, EDMCs can promote Pulmonary metastasis in Hepatocellular Carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-hang Zhu.
Funding
National Natural Science Foundation of China (81972677, 82103331), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515011022, 2022A1515010547).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09